Показано 0 из 0
Дата |
---|
22:22 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
21.77
|
21.78
|
22.26
|
21.74
|
22.47
|
21.75
|
|
|
3 724 421.84
|
2 117.00
|
20.51
|
22.57
|
21.92
|
21.51
|
22.20
|
22.10
|
|
|
5 865 082.35
|
3 087.00
|
19.55
|
21.93
|
21.53
|
20.76
|
22.21
|
21.92
|
|
|
12 070 801.57
|
6 405.00
|
21.53
|
22.39
|
23.66
|
23.45
|
23.70
|
23.46
|
|
|
3 766 918.31
|
2 148.00
|
23.39
|
23.99
|
23.80
|
23.60
|
23.87
|
23.75
|
|
|
1 886 599.79
|
1 365.00
|
23.39
|
23.75
|
23.60
|
23.45
|
23.75
|
23.71
|
|
|
2 254 605.37
|
1 244.00
|
23.50
|
23.75
|
23.65
|
23.355
|
23.71
|
23.53
|
|
|
2 212 716.08
|
1 584.00
|
23.65
|
23.80
|
23.23
|
23.19
|
23.78
|
23.705
|
|
|
2 494 950.12
|
1 791.00
|
22.60
|
23.79
|
22.93
|
22.93
|
23.46
|
23.28
|
|
|
3 172 070.94
|
2 060.00
|
22.57
|
23.20
|
22.56
|
22.56
|
23.06
|
22.85
|
|
|
2 929 491.85
|
1 862.00
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.